Back to today’s briefing

Story perspectives

AbbVie Boosts Earnings Forecast Amid Skyrizi Sales Surge

4/25/2025

41 9

Summary

Story summary

AbbVie increased its full-year earnings forecast, fueled by robust sales of Skyrizi and Rinvoq, surpassing Humira.
Skyrizi sales surged 71% to $3.43 billion, while Rinvoq grew 57% to $1.72 billion.
Total sales hit $13.34 billion, exceeding expectations, with adjusted earnings of $2.46 per share.
Analysts worry about potential effects of pharmaceutical tariffs and economic uncertainty on aesthetics sales.

1 of 1

Story summary

AbbVie increased its full-year earnings forecast, fueled by robust sales of Skyrizi and Rinvoq, surpassing Humira.
Skyrizi sales surged 71% to $3.43 billion, while Rinvoq grew 57% to $1.72 billion.
Total sales hit $13.34 billion, exceeding expectations, with adjusted earnings of $2.46 per share.
Analysts worry about potential effects of pharmaceutical tariffs and economic uncertainty on aesthetics sales.